Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211 At-CXCR4 monoclonal antibody

To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ( At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of At...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-04, Vol.10 (1), p.6810
Hauptverfasser:	Oriuchi, Noboru, Aoki, Miho, Ukon, Naoyuki, Washiyama, Kohshin, Tan, Chengbo, Shimoyama, Saki, Nishijima, Ken-Ichi, Takahashi, Kazuhiro, Ito, Hiroshi, Ikezoe, Takayuki, Zhao, Songji
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - therapeutic use Astatine - therapeutic use Humans Iodine Radioisotopes Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - therapy Male Mice, Inbred BALB C Mice, Nude Muscles - pathology Neoplastic Stem Cells - pathology Organ Specificity Radiation Dosage Radioimmunotherapy Receptors, CXCR4 - immunology Tissue Distribution U937 Cells Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To explore stem-cell-targeted radioimmunotherapy with α-particles in acute myelogenous leukemia (AML), pharmacokinetics and dosimetry of the At-labeled anti-C-X-C chemokine receptor type 4 monoclonal antibody ( At-CXCR4 mAb) were conducted using tumor xenografted mice. The biological half-life of At-CXCR4 mAb in blood was 15.0 h. The highest tumor uptake of 5.05%ID/g with the highest tumor-to-muscle ratio of 8.51 ± 6.14 was obtained at 6 h. Radiation dosimetry estimated with a human phantom showed absorbed doses of 0.512 mGy/MBq in the bone marrow, 0.287 mGy/MBq in the kidney, and
ISSN:	2045-2322